Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Krystal Biotech, Inc. (KRYS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
48.72+1.05 (+2.20%)
At close: 4:00PM EDT
48.72 0.00 (0.00%)
After hours: 04:01PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close47.67
Open48.84
Bid48.73 x 800
Ask67.15 x 800
Day's Range47.40 - 49.85
52 Week Range40.04 - 87.29
Volume156,608
Avg. Volume117,975
Market Cap1.082B
Beta (5Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)-2.16
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est98.43
  • GlobeNewswire

    Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCT

    PITTSBURGH, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present pre-clinical pharmacology data on its second genetic pulmonary disease candidate KB408, for the treatment of alpha-1 antitrypsin deficiency (AATD), at the upcoming European Society of Gene & Cell Therapy (ESGCT) Virtual Congress held October 19 – 22, 2021. AATD is a rare genetic disorder that predisposes aff

  • GlobeNewswire

    Krystal Biotech and GeneDx Announce Collaboration to Provide No-charge Genetic Testing for Patients with Suspected Dystrophic Epidermolysis Bullosa (DEB)

    The Krystal Decode DEB™ program is designed to shorten time to accurate diagnosis and facilitate the delivery of optimal carePITTSBURGH and GAITHERSBURG, Md., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, and GeneDx, Inc., a leader in genomic analysis and a wholly-owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced a collaboration offering no-char

  • GlobeNewswire

    Krystal Biotech to Present at the Chardan 5th Annual Genetic Medicines Conference

    PITTSBURGH, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced its participation in the Chardan Virtual 5th Annual Genetic Medicines Conference, taking place October 4-5, 2021. Krish Krishnan, Chairman and CEO at Krystal Biotech, will participate in a fireside chat, and Whitney Ijem, SVP, Strategy & Business Development, will join a panel discussion on the utility of non-traditional viral v

Advertisement
Advertisement